Cantor Fitzgerald set a $10.00 target price on Bellicum Pharmaceuticals (NASDAQ:BLCM) in a research note issued to investors on Friday. The firm currently has a buy rating on the biopharmaceutical company’s stock.
Several other research firms have also recently commented on BLCM. Zacks Investment Research cut shares of Bellicum Pharmaceuticals from a buy rating to a hold rating in a research report on Friday, January 12th. SunTrust Banks decreased their target price on shares of Bellicum Pharmaceuticals to $18.00 and set a buy rating for the company in a research report on Wednesday, January 31st. Raymond James Financial restated a buy rating on shares of Bellicum Pharmaceuticals in a research report on Tuesday, December 12th. ValuEngine upgraded shares of Bellicum Pharmaceuticals from a strong sell rating to a sell rating in a research report on Wednesday, January 3rd. Finally, BidaskClub lowered shares of Bellicum Pharmaceuticals from a sell rating to a strong sell rating in a research note on Thursday, January 11th. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and five have given a buy rating to the stock. The company currently has a consensus rating of Hold and a consensus price target of $16.88.
Bellicum Pharmaceuticals (NASDAQ BLCM) opened at $7.28 on Friday. Bellicum Pharmaceuticals has a 1 year low of $5.02 and a 1 year high of $15.55. The company has a quick ratio of 6.08, a current ratio of 6.08 and a debt-to-equity ratio of 0.23. The company has a market cap of $242.10, a PE ratio of -2.43 and a beta of 0.70.
Several large investors have recently modified their holdings of BLCM. Point72 Asset Management L.P. acquired a new stake in shares of Bellicum Pharmaceuticals in the 3rd quarter worth approximately $4,723,000. Prosight Management LP acquired a new stake in Bellicum Pharmaceuticals during the fourth quarter valued at approximately $2,534,000. Vanguard Group Inc. lifted its stake in Bellicum Pharmaceuticals by 13.6% during the second quarter. Vanguard Group Inc. now owns 1,206,436 shares of the biopharmaceutical company’s stock valued at $14,092,000 after purchasing an additional 144,854 shares during the last quarter. Millennium Management LLC acquired a new stake in Bellicum Pharmaceuticals during the fourth quarter valued at approximately $1,045,000. Finally, Goldman Sachs Group Inc. lifted its stake in Bellicum Pharmaceuticals by 223.5% during the second quarter. Goldman Sachs Group Inc. now owns 138,000 shares of the biopharmaceutical company’s stock valued at $1,612,000 after purchasing an additional 95,336 shares during the last quarter. 56.20% of the stock is owned by institutional investors.
ILLEGAL ACTIVITY WARNING: This article was first reported by Ticker Report and is owned by of Ticker Report. If you are accessing this article on another publication, it was illegally copied and republished in violation of international copyright and trademark law. The original version of this article can be accessed at https://www.tickerreport.com/banking-finance/3224872/bellicum-pharmaceuticals-blcm-given-a-10-00-price-target-by-cantor-fitzgerald-analysts.html.
Bellicum Pharmaceuticals Company Profile
Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system.
Receive News & Ratings for Bellicum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.